A new once-weekly antibiotic, Dalbavancin (Durata Therapeutics, INC), has shown great promise and was recently approved by the FDA for patients with SSTI cause by gram-positive microorganisms, including MRSA. Dalbavancin has been shown to have equal efficacy for SSTI caused by gram-positive ...
Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective StudyAcute osteomyelitis is typically caused by Gram-positive pathogens, commonly antibiotic-resistantStaphylococcusspecies. Standard antibiotic treatment is challenging due to required multiple daily doses, ...